PRA Health Sciences Shares Outstanding 2013-2018 | PRAH

PRA Health Sciences shares outstanding history from 2013 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • PRA Health Sciences shares outstanding for the quarter ending September 30, 2018 were 0.067B, a 0.96% increase year-over-year.
  • PRA Health Sciences 2017 shares outstanding were 0.066B, a 2.05% increase from 2016.
  • PRA Health Sciences 2016 shares outstanding were 0.064B, a 1.97% increase from 2015.
  • PRA Health Sciences 2015 shares outstanding were 0.063B, a 47.35% increase from 2014.
PRA Health Sciences Annual Shares Outstanding
(Millions of Shares)
2017 66
2016 64
2015 63
2014 43
2013 39
2012 40
PRA Health Sciences Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 67
Q2 2018 66
Q1 2018 66
Q4 2017 66
Q3 2017 66
Q2 2017 66
Q1 2017 65
Q4 2016 64
Q3 2016 65
Q2 2016 64
Q1 2016 60
Q4 2015 63
Q3 2015 64
Q2 2015 63
Q1 2015 63
Q4 2014 43
Q3 2014 42
Q2 2014 40
Q1 2014 40
Q4 2013 0
Q3 2013 39
Q2 2013 40
Q4 2012 0
Sector Industry Market Cap Revenue
Medical Medical Services $6.613B $2.259B
PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $54.401B 11.24
ICON (ICLR) Ireland $7.342B 23.01
Charles River Laboratories (CRL) United States $6.190B 21.70
Premier (PINC) United States $5.294B 18.04
HealthEquity (HQY) United States $5.236B 109.60
INC Research Holdings (SYNH) United States $5.099B 20.58
Teladoc (TDOC) United States $4.024B 0.00
NovoCure (NVCR) Jersey $2.835B 0.00
AMN Healthcare Services Inc (AMN) United States $2.676B 18.36
BioTelemetry (BEAT) United States $1.998B 35.29
Medpace Holdings (MEDP) United States $1.982B 24.53
Healthways (TVTY) United States $1.499B 18.44
Intrexon (XON) United States $1.343B 0.00
IKang Healthcare (KANG) China $1.129B 56.07
CareDx (CDNA) United States $1.027B 0.00
Natera (NTRA) United States $0.953B 0.00
China Cord Blood (CO) China $0.802B 21.29
Surgery Partners (SGRY) United States $0.665B 0.00
Apollo Medical Holdings (AMEH) United States $0.629B 0.00
Establishment Labs Holdings (ESTA) $0.566B 0.00
Civitas Solutions (CIVI) United States $0.520B 10.24
OncoCyte (OCX) United States $0.069B 0.00
Interpace Diagnostics (IDXG) United States $0.033B 0.00
Cancer Genetics (CGIX) United States $0.015B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.004B 0.00